UBE2N and cancer: Ubc13 cancer mutations in positions likely to disrupt the active site structure are Thr73Ile (liver), Ile75Met (uterine), Pro78Leu (melanoma), and Arg85Ile/Lys (lung adenocarcinoma/multiple myeloma).